Krónikus limfoid leukémia (CLL): vizsgálatok itt: Spanyolország
43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Where
- Barcelona, Madrid, Murcia, Oviedo, Santiago de Compostela, Sevilla
- Életkor
- 18 év and over
- People
- 306 worldwide
- Run by
- Newave Pharmaceutical Inc
See details and how to joinNCT07342478 · EU 2026-525656-28-00 - 2. fázisTaking peopleA Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
- Where
- Salamanca
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07709000 · EU 2025-522242-49-00 - 1. fázisTaking peopleA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Barcelona, Madrid, Pamplona
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00 - 3. fázisTaking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- L'Hospitalet Del Llobregat, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - 1. fázisTaking peopleA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Barcelona
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - No phaseTaking peoplePICAROS - Acalabrutinib RWE on 1L CLL in Spain
- Where
- Alicante, Almería, Barcelona, Córdoba, Donostia / San Sebastian, El Palmar, Galdakao, Granada, Granollers, Guadalajara, Jaén, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lleida, Madrid, Majadahonda, Málaga, Marbella, Murcia, Ourense, Oviedo, Palma de Mallorca, Salamanca, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Segovia, Seville, Terrassa, Toledo, Valencia, Valladolid, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 315
- Run by
- AstraZeneca
See details and how to joinNCT05999877 - 2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Oviedo, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Sevilla
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - 1. fázisCsak meghívásosA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Barcelona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - 4. fázisTaking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Santander, Seville
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - 4. fázisTaking peopleAcalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
- Where
- Barcelona, Madrid, Sevilla
- Életkor
- 18 év and over
- People
- 33 worldwide
- Run by
- AstraZeneca AB
See details and how to join2023-510147-37-00 · EU 2023-510147-37-00 - 1/2. fázisTaking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Barcelona, Madrid, Palma, Santiago de Compostela, Valencia
- Életkor
- 18 év and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- A Coruña, Alicante, Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - 1/2. fázisTaking peopleA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Where
- L'Hospitalet de Llobregat, Madrid, Salamanca
- Életkor
- 18 év and over
- People
- 258 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00 - 3. fázisTaking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Marbella, Salamanca, Santander, Sevilla
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - 2. fázisTaking peopleMAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
- Where
- Barcelona, Granada, Madrid, Majadahonda
- Életkor
- 18 év to 130 év
- People
- 80 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07024706 · EU 2024-518858-17-00 - 3. fázisTaking peopleSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Badalona, Barcelona, Elche, Madrid, Santander
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 3. fázisTaking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Barcelona, L'Hospitalet de Llobregat, Majadahonda, Pozuelo de Alarcón, Salamanca, San Cristobal De La Laguna
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - 1/2. fázisTaking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 1 év to 17 év
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Barcelona, Madrid, Majadahonda, Valencia
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 3. fázisTaking peopleA phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
- Where
- Alicante, Badalona, Barcelona, Córdoba, Donostia, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Marbella, Murcia, Oviedo, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 746 worldwide
- Run by
- University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00 - 3. fázisTaking peopleA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Badalona, Cáceres, Madrid, Pamplona, Valencia, Clinica Universidad De Navarra, Hospital Universitario Quironsalud Madrid
- Életkor
- 18 év and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Badalona, Burgos, Las Palmas De Gran Canaria, Madrid, Majadahonda, Palma, Sevilla
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 3. fázisTaking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Granada, Madrid, Majadahonda, Murcia
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - 4. fázisTaking peopleAcalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
- Where
- Barcelona, Madrid, Seville
- Életkor
- 18 év to 130 év
- People
- 60 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06651970